These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38710155)

  • 61. Non-activated prothrombin complex concentrates for major bleeding in patients on apixaban and rivaroxaban.
    Sheikh-Taha M
    Intern Emerg Med; 2020 Sep; 15(6):1123-1124. PubMed ID: 31664661
    [No Abstract]   [Full Text] [Related]  

  • 62. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy.
    Khorsand N; Kooistra HA; van Hest RM; Veeger NJ; Meijer K
    Thromb Res; 2015 Jan; 135(1):9-19. PubMed ID: 25480313
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
    Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
    Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
    Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D
    J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
    Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
    Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series.
    Schultz NH; Lundblad R; Holme PA
    J Med Case Rep; 2018 May; 12(1):138. PubMed ID: 29764497
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
    Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
    Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia.
    Rockhold M; Kunkel L; Lacoste JL; Szymanski T; Rothenberg P; Zimmerman P; Minc S
    J Vasc Surg; 2024 Jun; 79(6):1466-1472.e1. PubMed ID: 38278371
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
    Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
    Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
    Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
    Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery.
    Schmidt LE; Hinton MS; Martin ND
    J Pharm Pract; 2024 Feb; 37(1):74-79. PubMed ID: 36083782
    [No Abstract]   [Full Text] [Related]  

  • 76. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
    Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage.
    Scott R; Kersten B; Basior J; Nadler M
    J Emerg Med; 2018 Jun; 54(6):861-866. PubMed ID: 29510892
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study.
    Margraf DJ; Seaburg S; Beilman GJ; Wolfson J; Gipson JC; Chapman SA
    BMC Emerg Med; 2020 Nov; 20(1):93. PubMed ID: 33243152
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
    Ueno EI; Fujibayashi K; Sawaguchi J; Yasuda Y; Takano S; Fujioka N; Kawai Y; Fujita H; Tanaka Y; Kajinami K
    J Thromb Thrombolysis; 2020 Aug; 50(2):371-379. PubMed ID: 32166540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.